Madrigal Pharmaceuticals
Madrigal Pharmaceuticals, Inc. is a biopharmaceutical company in the clinical development phase, concentrating its efforts on discovering and commercializing innovative treatments for cardiovascular, metabolic, and liver disorders. Its most advanced drug candidate, resmetirom, functions as a liver-targeted selective thyroid hormone receptor-ß agonist, currently undergoing late-stage (Phase III) clinical trials for managing non-alcoholic steatohepatitis (NASH). The company's pipeline also features MGL-3745, which serves as a secondary or backup compound to resmetirom. Madrigal holds a collaborative agreement with Hoffmann-La Roche, encompassing research, development, and commercialization activities. The company's operations are based out of West Conshohocken, Pennsylvania.
Visit website
LLY Eli Lilly and Company |
$1408.99 | -1.58% |
JNJ Johnson & Johnson |
$279.42 | -1.11% |
ABBV AbbVie |
$293.29 | -0.43% |
MRK Merck & Co. |
$143.53 | -0.64% |
UNH UnitedHealth Group Incorp… |
$394.17 | -4.33% |